Skip to product information
1 of 1

FDA ANDA 217250, ERIBULIN MESYLATE, BAXTER HLTHCARE CORP, 10/01/2024

FDA ANDA 217250, ERIBULIN MESYLATE, BAXTER HLTHCARE CORP, 10/01/2024

Regular price $225.95 USD
Regular price Sale price $225.95 USD
Sale Sold out

Contents: Summary Basis of Approval of CMC (Chemistry, Manufacture and Control) section of Drug Substance for the Eribulin Mesylate Injection, 1mg/2mL (0.5mg/mL) application #A217250, approved on October 1, 2024.

ANDA: 217250
Company: BAXTER HLTHCARE CORP
Drug Name: ERIBULIN MESYLATE
Active Ingredients: ERIBULIN MESYLATE
Strength: 1MG/2ML (0.5MG/ML)
Dosage Form/Route: SOLUTION;INTRAVENOUS
Action Date: 10/01/2024
Marketing Status: Prescription
Submission Classification: ORIG-1

54 Pages

View full details
FOIA Pro

This drug has a lot more FDA history than one product page can show

FOIA Pro gives you full-text search across 70,000+ FDA FOIA records, from 2020 through today, plus a monthly monitor tracking new requests as they close.
  • Full-text search across every FDA FOIA log since 2020
  • Warning letters, approval records, and correspondence in one place
  • Monthly FDA FOIA Monitor newsletter, included
  • Cancel anytime, monthly or annual billing
Get FOIA Pro
Live search · FOIA database
Searching related FDA records…
ClosedTypeSubjectOutcome